A senior Jefferies banker, Sage Kelly, is on leave after intense publicity around salacious allegations made by his wife in divorce proceedings.» Read More
Better patient survival rates prompted Bristol-Myers Squibb to bring an early end to an advanced study of a potential treatment for one of the most common forms of lung cancer. Last month, the Food and Drug Administration granted accelerated approval to Opdivo as a treatment for a deadly form of skin cancer that cannot be removed by surgery and has spread...
Dec 6- Merck& Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting. Craig Moskowitz, the study's principal investigator from Memorial Sloan Kettering Cancer...
Dec 6- Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday. Margaret Shipp, co-lead investigator of the Checkmate-039 study from Dana-Farber Cancer Institute in Boston. The results were being...
Sept 29- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Seattle Genetics said it expected to submit a marketing application to FDA for the drug's supplemental use in 2015..
Sept 29- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Consolidation therapy is given to cancer patients who have undergone initial therapy and kills any cancer cells that may be left in the body.
After a string of mergers, Cramer thinks investors may be looking at significantly higher valuations in parts of the market.
Jim Cramer hit the road Wednesday to investigate the prospects of 4 firms headquartered in Seattle.
Some of Wednesday's midday movers:
There are a handful of stocks out there that the market loves and should take even higher by the end of the year, CNBC's Jim Cramer said Thursday.
Cramer always notes superlatives in any stock. What does he think of this play now?
We could be witnessing the beginning of a merger wave in biotech, Jim Cramer said Tuesday.
The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
TheStreet.com suggests stocks that could pop on their earnings reports.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
TheStreet.com offers up 13 biotech predictions for 2013.
BOTHELL, Wash.-- Seattle Genetics Inc. said Tuesday that pharmaceutical giant Abbott Laboratories has agreed to pay $25 million plus potential milestone payments for the biotech firm's experimental antibodies to fight cancer.
The "Mad Money" host spoke with the CEO of Seattle Genetics about the safety of the biotech space.
Savvy investors know that making money on the “ASCO trade” means getting in early as cancer drug stocks typically trade up into the closely watched medical meeting.